Bibliographic Details
| Title: |
Prurigo nodular: a propósito de un caso tratado con dupilumab. |
| Alternate Title: |
Prurigo nodularis: a case report treated with dupilumab. |
| Authors: |
Libertad Ortega-Núñez, Diana1, Marisol González-Salas, Ofelia2, Liliana Benites-Gutiérrez, Cinthia1, Barrera-Jácome, Araceli3, Rincón-Pérez, Catalina4 |
| Source: |
Dermatología Revista Mexicana. set/oct2021, Vol. 65 Issue 5, p787-797. 11p. |
| Abstract (English): |
BACKGROUND: Prurigo nodularis is an inflammatory, chronic and intensely pruritic dermatosis, rare and difficult to treat. It is characterized clinically by hyperkeratotic nodules and papules secondary to repetitive scratching, it can be localized to a body segment or generalized with symmetric distribution. CLINICAL CASE: A 68-year-old male patient with a history of smoking, systemic arterial hypertension and penile carcinoma in complete remission, who had been following up by dermatologists since 2014 for severe prurigo nodularis confirmed by biopsy and with serious quality of life impairment in recent years, without response to the various treatment modalities that exist for the condition and which was contraindicated for immunosuppressant medication. Therefore, it was decided to start therapy with dupilumab using the established dose for the treatment of atopic dermatitis of 600mg subcutaneous induction phase and then doses of 300mg every 2 weeks in the maintenance phase. Monthly follow-up was given finding significant clinical and symptomatic response in the first 3 months, without presenting adverse effects to therapy. CONCLUSIONS: Dupilumab is a good alternative in patients with severe prurigo nodularis with failure of previous treatments or who have contraindications to the use of immunosuppressants. [ABSTRACT FROM AUTHOR] |
| Abstract (Spanish): |
ANTECEDENTES: El prurigo nodular es una dermatosis inflamatoria, crónica e intensamente pruriginosa, poco frecuente y de difícil tratamiento. Se caracteriza clínicamente por pápulas y nódulos hiperqueratósicos secundarios al rascado repetitivo, que pueden estar localizados a un segmento corporal o generalizados con distribución simétrica. CASO CLÍNICO: Paciente masculino de 68 años con antecedente de tabaquismo, hipertensión arterial sistémica y carcinoma de pene en remisión completa. Inició seguimiento por el servicio de Dermatología desde 2014 por prurigo nodular severo confirmado por biopsia y con afectación grave a la calidad de vida en los últimos años, sin respuesta a las distintas modalidades de tratamiento que existen contra el padecimiento y con contraindicación para el inicio de inmunosupresores, por lo que decidió iniciarse tratamiento con dupilumab con la dosis establecida para el tratamiento contra la dermatitis atópica de 600 mg subcutánea en la fase de inducción y después dosis de 300 mg cada dos semanas en la fase de mantenimiento. Se dio seguimiento mensual encontrando significativa respuesta clínica y sintomática en los primeros tres meses, sin efectos secundarios a la terapia. CONCLUSIONES: El dupilumab es una buena alternativa en pacientes con prurigo nodular grave con falla a tratamientos previos o que tengan contraindicación a la administración de inmunosupresores. [ABSTRACT FROM AUTHOR] |
|
Copyright of Dermatología Revista Mexicana is the property of Edicion y Farmacia S.A. de C.V. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
MedicLatina |
